chimerix

Durham biopharma sells rights to smallpox countermeasure for up to $337M

Posted by WRAL TechWire | May 17, 2022

Chimerix has agreed to sell its smallpox countermeasure to Emergent BioSolutions in a deal worth as much as $337 million.

Earnings reports: Chimerix, Bandwidth, Lending Tree, Aerie

Posted by WRAL TechWire | Mar 1, 2022

Triangle and North Carolina firms continue to report quarterly earnings. Here are several of the latest.

Earnings news: Duke Energy, CommScope, BioCryst, Chimerix

Posted by WRAL TechWire | Aug 5, 2021

Duke Energy, CommScope and two biotech firms in the Triangle report their financials as earnings season continues.

Durham biopharma secures FDA green light for its antiviral smallpox therapy

Posted by WRAL TechWire | Jun 10, 2021

The U.S. Food and Drug Administration has just granted Chimerix marketing approval for the tablet and oral suspension formulations of its smallpox treatment TEMBEXA (brincidofovir).

Earnings news: CommScope, Biocryst, BDSI, Chimerix, Aerie, VTV,

Posted by WRAL TechWire | May 6, 2021

A host of companies across North Carolina are reporting earnings this week, including CommScope, Biocryst, BDSI and more. Here’s a look:

Here’s the back story behind a $100M fund raiser for Chimerix: A growing oncology pipeline

Posted by WRAL TechWire | Jan 21, 2021

The pipeline of cancer drug developer Chimerix is growing, and the biotech has raised $100 million to support it. NCBiotech writer Frank Vinluan has he full story.

Chimerix surges following news of $100M stock offering, pricing shares

Posted by WRAL TechWire | Jan 21, 2021

Shares in Durham biotech Chimerix surged some 13% Wednesday on news of an $86 million stock offering – and the gains held after the firm priced shares at $8.50.

Durham biotech Chimerix looks to raise as much as $86M

Posted by WRAL TechWire | Jan 20, 2021

Biopharmaceutical firm Chimerix is looking to raise as much as $86 million through a stock offering, the company announced Tuesday after markets closed.